GlassScriptPhysician profile
Toni Mcfadden
NPI 1205859311
$2,608.20
in general payments reported to CMS, 2019-2025
26 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $292 · 2023: $382 · 2024: $513 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $369.79 | 2022-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $367.56 | 2021-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $275.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $207.00 | 2022-2025 | Verquvo, Winrevair |
| Esperion Therapeutics, INC. | $150.99 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $141.64 | 2021-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $140.69 | 2021-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $97.68 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.14 | 2022-2023 | |
| United Therapeutics Corporation | $78.95 | 2021-2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.94 | 2021-2023 | Lifevest |
| Edwards Lifesciences Corporation | $75.07 | 2021-2025 | Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.30 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $64.84 | 2023-2024 | Farxiga, Wainua |
| Pfizer INC. | $62.91 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.46 | 2023-2024 | Xarelto |
| Amarin Pharma, INC. | $48.26 | 2021 | |
| Abbott Laboratories | $47.02 | 2021-2025 | 2nd Gen Centrimag Primary Console |
| Alnylam Pharmaceuticals INC. | $32.14 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $29.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.03 | 2023 | Evkeeza |
| Abiomed | $25.20 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $23.48 | 2024 | |
| Scpharmaceuticals INC. | $20.55 | 2025 | |
| Irhythm Technologies, INC. | $15.70 | 2022 | |
| Novo Nordisk INC | $14.35 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.